<?xml version="1.0" encoding="UTF-8"?>

	
		

<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: 9 most important AIDS stories of 2008</title>
	<atom:link href="http://www.365gay.com/living/9-most-important-aids-stories-of-2008/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.365gay.com/living/9-most-important-aids-stories-of-2008/</link>
	<description>The daily news source for the gay, lesbian, bisexual and transgender community</description>
	<lastBuildDate>Sun, 29 Jan 2012 17:11:12 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.4</generator>
	<item>
		<title>By: John X</title>
		<link>http://www.365gay.com/living/9-most-important-aids-stories-of-2008/comment-page-1/#comment-33350</link>
		<dc:creator>John X</dc:creator>
		<pubDate>Tue, 02 Dec 2008 20:02:07 +0000</pubDate>
		<guid isPermaLink="false">http://www.365gay.com/?p=4386#comment-33350</guid>
		<description>I would add to the list Sudhir Paul and Stephanie Planque of U Texas Medical School at Austin&#039;s work on &quot;abzymes&quot; that use catalytic activity to target a small section of HIV&#039;s gp120 protein that is identical in most strains, required to infect cells and also hard for human antibodies to find.  Each unit of the &quot;abzymes&quot; can, in theory, inactivate thousands of copies of the virus.  (They defeat a copy, then move on to another.)  Human trials are planned and cannot come soon enough.  They plan abzyme therapy by intravenous infusion to remove free virus coupled with nasal vaccination using a synthetic, chemically modified fragment of the virus.  They are looking for participants in the study in late 2009, and already will collect names of potential volunteers.</description>
		<content:encoded><![CDATA[<p>I would add to the list Sudhir Paul and Stephanie Planque of U Texas Medical School at Austin&#8217;s work on &#8220;abzymes&#8221; that use catalytic activity to target a small section of HIV&#8217;s gp120 protein that is identical in most strains, required to infect cells and also hard for human antibodies to find.  Each unit of the &#8220;abzymes&#8221; can, in theory, inactivate thousands of copies of the virus.  (They defeat a copy, then move on to another.)  Human trials are planned and cannot come soon enough.  They plan abzyme therapy by intravenous infusion to remove free virus coupled with nasal vaccination using a synthetic, chemically modified fragment of the virus.  They are looking for participants in the study in late 2009, and already will collect names of potential volunteers.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Krishna Stone</title>
		<link>http://www.365gay.com/living/9-most-important-aids-stories-of-2008/comment-page-1/#comment-33195</link>
		<dc:creator>Krishna Stone</dc:creator>
		<pubDate>Mon, 01 Dec 2008 17:21:03 +0000</pubDate>
		<guid isPermaLink="false">http://www.365gay.com/?p=4386#comment-33195</guid>
		<description>Thank you for including GMHC in your retrospective article.  Many blessings to you and 365Gay team on World AIDS Day.

Krishna Stone</description>
		<content:encoded><![CDATA[<p>Thank you for including GMHC in your retrospective article.  Many blessings to you and 365Gay team on World AIDS Day.</p>
<p>Krishna Stone</p>
]]></content:encoded>
	</item>
</channel>
</rss>
		
	
